DYNACIRC CR
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Jun 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DYNACIRC CR is an extended-release oral tablet approved in 1994 as a small-molecule NDA sponsored by GSK. The specific therapeutic indication and mechanism of action are not publicly specified in available data. This product represents a mature small-molecule therapeutic with extended-release formulation technology.
LOE Approaching
As LOE approaches, commercial team size is likely contracting; roles focus on maximizing remaining exclusivity period and managing transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DYNACIRC CR as LOE approaches offers experience in late-stage product management, generic defense strategies, and organizational transition planning. This role suits professionals seeking hands-on experience with compliance, market protection, and wind-down operations rather than growth-focused brand building.
Brand ManagerField Sales Representative
Worked on DYNACIRC CR at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.